Episurf Medical AB Class B · OMXSTO:EPIS_B
Episurf Medical AB Class B — ProHearings, Stockholm 2017
24 slides from Episurf Medical AB Class B's conference presentation, Feb 17, 2017
Slide 1: Addressing a global health problem
Addressing a global health problem ProHearings, Stockholm 17 February 2017 Pål Ryfors, Acting CEO and CFO
Slide 2: Introduction
Introduction Focus of today Today’s presenter 1. The problem Pål Ryfors • Acting CEO and CFO from Jan 17 2. Our solution • CFO Dec 15 – Jan 17 • Background from the banking industry, 3. Our results most recently CFO at Marginalen Bank 4. Company and previously Head of Group Controlling at Hoist Fina
Slide 3: The problem
The problem • Several hundred million individuals are suffering from severe knee pain leading to significant loss off quality of life Negative Severe pain Lack of impact on and weak treatment quality of mobility methods life 3
Slide 4: The problem (cont.)
The problem (cont.) • A lengthy, degenerative and often very painful process is preceding the full development of osteoarthritis, incurring significant costs to the society • Today there is no cure for osteoarthritis – Joint cartilage has poor capacity to regenerate • There is a significant number o
Slide 5: Targeting the GAP patient
Targeting the GAP patient Lesion size L The treatment of knee Cell treatments TKA joint disease for the middle-aged patient is challenging M Episealer® Epiealer® UKA Micro fracture S Mosaicplasty Synthetic grafts 30 50 70 Age 5
Slide 6: Targeting the GAP patient (cont.)
Targeting the GAP patient (cont.) 128 Market example >5 70 million 67 knee 39 arthroscopies 3 Knee Debridement Other (incl. Knee of which OA arthroscopies & Micro ACI) replacements (96%) >2 fracture million knee replacements Continued establishment of the Episealer® technology within the treatment a
Slide 7: A growing market
A growing market • The GAP-patient: Too old for biology – too young for TKA – Your best years 200 million – Demand for an active life style patients worldwide • Osteoarthritis occurs earlier in the middle age and suffer from knee increases following an ageing population and increased osteoarthritis
Slide 8: Scratching on the surface…
Scratching on the surface… Market shares Market shares joint reconstruction market, $16.5bn1 knee reconstruction market, $8.0bn2 Extremities Other 10% 14% ZB S&N 34% 11% Knee 49% Hips 41% DePuy 19% 1. The Orthopaedic industry annual report 2015, publish by Orthoworld 8 2. The Orthopaedic industry an
Slide 9: The unique solution
The unique solution Patient Minimally Simplified specific invasive 9
Slide 10: Market validation, clinical results, generating revenues
Market validation Clinical results Generating revenues Strong user adoption 10
Slide 11: Our technology
Our technology STEP 2 STEP 3 STEP 4 STEP 1 3D damage Patient-specific The unique Collecting MRI assessment implants surgical kit 11
Slide 12: Epioscopy 3D damage marking
Epioscopy 3D damage marking • Digital, 3D based analysis of the knee joint • Analysis of cartilage quality and underlying bone quality through creation of a digital replica of the knee joint • Non-invasive • Simple communication and approval process 12
Slide 13: The Episealer family
The Episealer family • An implant portfolio for various parts of the knee joint • Each implant is customized to fit the unique anatomy of each individual patient • Using Hydroxiapatite and Titanium coating for long- and short- term bone fixation 13
Slide 14: Epiguide – surgical tools
Epiguide – surgical tools • Just-in-time delivery – no inventory at hospitals • Simplified the procedure • 20 – 30 minutes “skin-to-skin” 14
Slide 15: The patient
The patient “FOR THE FIRST TIME IN 25 YEARS I COULD RUN AGAIN WITH NO PAIN OR SWELLING” …41-year-old Nicklas from Sweden has suffered from knee pain for more than 2 decades. Prior to asking for the Episealer treatment he had undergone 6 procedures with no lasting effect, resulting in decreasing life
Slide 16: A lengthy and painful process
A lengthy and painful process Pre-OA OA Biologics Synthetic grafts / Re-surfacing UKA TKA Episurf Medical’s goal is to mainstream patient- The lengthy degenerative process leading specific treatment options up to OA often starts with a trauma as a new standard within the leading to a small damage in
Slide 17: How Episurf is solving the failure rate
How Episurf is solving the failure rate What Episurf avoids What Episurf do Lack of defined indication and/or weak • Pre-surgical assessment to find correct bones/surrounding cartilage indication – addressing the pain Edges from “almost perfect” fit creates • Patient specific to adjust to individual
Slide 18: Clinical results
Clinical results > 4,0 yrs 2 > 3,5 yrs 4 > 3,0 yrs 10 > 2,5 yrs 16 > 2,0 yrs 25 > 1,5 yrs 48 > 1,0 yrs 76 > 0,5 yrs 109 We are commercializing a novel technology, in a previously difficult to treat patient group, in a Performed 171 traditionally conservative sector – orthopaedic implants 18
Slide 19: Clinical results (cont.)
Clinical results (cont.) KOOS - Pain KOOS – Function daily living KOOS – Quality of Life VAS 100 100 100 100 75 75 75 75 50 50 50 50 25 25 25 25 0 0 0 0 Pre-op 3m 12m Pre-op 3m 12m Pre-op 3m 12m Pre-op 3m 12m • Correct implant positioning • Joint space preserved and no adverse events • Significant i
Slide 20: From idea to concept to commercialization
From idea to concept to commercialization • Associate Professor Leif Ryd: Career within knee surgery and knee arthroscopy ”How do we treat early, focal cartilage ? • lesions? ... and in what way might this impact the development of osteoarthritis?” Commercialization Listed on OMX First clinical and
Slide 21: Strong value proposition to stakeholders
Strong value proposition to stakeholders • Safe procedure and short recovery time • Clinically superior pain and function improvement Patients • Predictable results and increased durability of treatment • Superior technology for pre-surgical decision-making Physicians • Minimal procedure length and
Slide 22: Episurf company
Episurf company • Headquartered in Stockholm, Sweden EPIS B, Nasdaq Stockholm 25 • 27 employees 20 • Highly experienced Clinical Advisory Board 15 SEK • 5 CE approved products 10 • Listed on Nasdaq Stockholm since June 2014 5 0 Dennis D. Stripe Executive Chairman Extensive experience from the orthop
Slide 23: Summary
Summary • At the forefront of the trend of patient specificity in med-tech • An unique and successful solution for a global health problem • Addressing an enormous and partly un-tapped market with a growing track-record of clinical results 23
Slide 24: Current rights issue
Current rights issue Terms in summary • New shares: 1:1 • Amount: SEK 120 million Q&A • Subscription price: SEK 7.50 • TERP discount: 37.5% • Guarantee: SEK 100 million • Other: Commitments from key shareholders and management Timetable in summary • Extra General Meeting on February 20 2017 • Last d